BeiGene, Ltd. (ONC:NASDAQ) closed at $416.54 on November 13, 2026, up 0.14% on the day. The stock trades 1.9% below its 52-week high of $424.73 and 64.0% above its 52-week low of $253.95. Over the past year, it gained 10.6%. BeiGene, Ltd. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, ONC closed higher on 122 days (48%). Its best day was October 15, 2026 (+6.43%) and its worst was February 26, 2026 (-8.48%). It never moved 10% or more in a single session. It opened at least 5% above the previous day's high 1 time.
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Find more stocks like ONC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.